By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Allergan Inc. v. Akorn Inc. et al.
1:11-cv-01270; filed December 21, 2011 in the District Court of Delaware
• Plaintiff: Allergan Inc.
• Defendants: Akorn Inc.; Akorn Ophthalmics Inc.
Infringement of U.S. Patent No. 7,842,714 ("Ketorolac Tromethamine Compositions for Treating Ocular Pain," issued November 30, 2010) following a Paragraph IV certification as part of Akorn's filing of an ANDA to manufacture a generic version of Allergan's Acuvail® (ketorolac tromethamine ophthalmic solution, used to treat pain and inflammation following cataract surgery). View the complaint here.
MSD Consumer Products, Inc. et al. v. Zydus Pharmaceuticals (USA) Inc.
3:11-cv-07437; filed December 21, 2011 in the District Court of New Jersey
• Plaintiffs: MSD Consumer Products, Inc.; Santarus, Inc.; Curators of the University of Missouri
• Defendants: Zydus Pharmaceuticals (USA) Inc.
Infringement of U.S. Patent Nos. 6,699,885 ("Substituted Benzimidazole Dosage Forms and Methods of Using Same," issued March 2, 2004), 6,489,346 (same title, issued December 3, 2002), 6,645,988 (same title, issue November 11, 2003), and 7,399,772 (same title, issued July 15, 2008) following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of MSD's Zegerid® OTC (omeprazole/sodium bicarbonate, used to treat heartburn and other symptoms associated with gastroesophageal reflux disease). View the complaint here.
Roche Palo Alto LLC et al. v. Dr. Reddy's Laboratories Ltd. et al.
1:11-cv-01264; filed December 20, 2011 in the District Court of Delaware
• Plaintiffs: Roche Palo Alto LLC; Genentech Inc.
• Defendants: Dr. Reddy's Laboratories Ltd.; Dr. Reddy's Laboratories Inc.
Infringement of U.S. Patent No. 6,083,953 ("2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol Derivative," issued July 4, 2000) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Roche's Valcyte® (valganciclovir hydrochloride, used to treat cytomegalovirus retinitis and cytomegalovirus disease). View the complaint here.
Pfizer Inc. et al. v. Sandoz Inc.
1:11-cv-01252; filed December 15, 2011 in the District Court of Delaware
• Plaintiffs: Pfizer Inc.; Wyeth LLC; Wyeth Pharmaceuticals Inc.
• Defendant: Sandoz Inc.
Pfizer Inc. et al. v. Intas Pharmaceuticals Ltd. et al.
1:11-cv-01253; filed December 15, 2011 in the District Court of Delaware
• Plaintiffs: Pfizer Inc.; Wyeth LLC; Wyeth Pharmaceuticals Inc.
• Defendants: Intas Pharmaceuticals Ltd.; Astron Research Ltd.; Accord Healthcare Ltd.; Accord Healthcare Inc. USA
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,362,718 ("Rapamycin Hydroxyesters," issued November 8, 1994) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Pfizer's Torisel® (temsirolimus injection, used to treat advanced renal cell carcinoma). View the Sandoz complaint here.
Comments